{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:08:27Z","timestamp":1789765707380,"version":"4.0.1"},"reference-count":48,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2011,7,18]],"date-time":"2011-07-18T00:00:00Z","timestamp":1310947200000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Iron overload is the most important cause of mortality in patients with thalassaemia major. Iron chelation is therefore a critical issue in the management of these patients and others with transfusion\u2010dependent haemoglobinopathies and congenital anaemias. In recent years, significant developments have been made in the assessment of iron overload, including the use of magnetic resonance imaging for measuring liver and cardiac iron. Advances in the modalities available for iron chelation, with the advent of oral iron chelators including deferiprone and deferasirox in addition to parenteral desferrioxamine, have expanded treatment options. A group of Australian haematologists has convened to formulate guidelines for managing iron overload on the basis of available evidence, and to describe best consensus practice as undertaken in major Australian Haemoglobinopathy units. The results of their discussions are described in this article, with the aim of providing guidance in the management of iron overload in these patients.<\/jats:p>","DOI":"10.1111\/j.1445-5994.2011.02527.x","type":"journal-article","created":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T13:58:56Z","timestamp":1306331936000},"page":"516-524","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Australian guidelines for the assessment of iron overload and iron chelation in transfusion\u2010dependent thalassaemia major, sickle cell disease and other congenital anaemias"],"prefix":"10.1111","volume":"41","author":[{"given":"P. J.","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lindeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Catley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. K.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7,18]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna\u2010Pignatti C","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02357-6"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/03630269.2010.485080"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.739"},{"key":"e_1_2_7_6_2","volume-title":"The Management of Sickle Cell Disease","author":"National Institutes of Health, National Heart, Lung, and Blood Institute","year":"2002"},{"key":"e_1_2_7_7_2","volume-title":"Standards for the Clinical Care of Children and Adults with Thalassaemia in the UK","author":"United Kingdom Thalassaemia Society","year":"2008"},{"key":"e_1_2_7_8_2","volume-title":"Guidelines for the Clinical Care of Patients with Thalassemia in Canada","author":"Anemia Institute for Research & Education and the Thalassemia Foundation of Canada","year":"2009"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12413"},{"key":"e_1_2_7_10_2","volume-title":"The Thalassemia International Federation Guidelines for the Clinical Management of Thalassemia 2nd Revised Edition","author":"Cappellini M\u2010D","year":"2008"},{"key":"e_1_2_7_11_2","volume-title":"Standards of Care Guidelines for Thalassemia","author":"Children's Hospital and Research Center Oakland","year":"2009"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1673.1988.tb02724.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07970.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(09)70003-7"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0177"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008033430503"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.2822"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.874487"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-148767"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.21433"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225615"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07907.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-109306"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3430"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00377.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181ec0f13"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10455"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0306"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.067001030.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.2002.0510"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2948"},{"key":"e_1_2_7_32_2","volume-title":"Oral Deferiprone for Iron Chelation in People with Thalassaemia (Review) \u2013 The Cochrane Library","author":"Roberts D","year":"2009"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.648790"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014696"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0838-z"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217455"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-250308"},{"key":"e_1_2_7_38_2","first-page":"3883","article-title":"Deferasirox (Exjade(R)) in pediatric patients with {beta}\u2010thalassemia: update of 4.7\u2010year efficacy and safety from extension studies","volume":"112","author":"Piga A","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2005.11.002"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.3109\/03630260903346924"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05202.x"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00335.x"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0820-0"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00519.x"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07848.x"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04412.x"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01092.x"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.012393"},{"key":"e_1_2_7_49_2","first-page":"CD000011","article-title":"Interventions for enhancing medication adherence","author":"Haynes RB","year":"2008","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2011.02527.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2011.02527.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T03:33:29Z","timestamp":1697340809000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2011.02527.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1111\/j.1445-5994.2011.02527.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2011.02527.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"2011-07-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}